Provided by Tiger Trade Technology Pte. Ltd.

Cartesian Therapeutics

7.36
+0.14001.94%
Post-market: 7.360.00000.00%19:30 EDT
Volume:200.38K
Turnover:1.49M
Market Cap:222.68M
PE:-1.27
High:8.05
Open:7.32
Low:7.29
Close:7.22
52wk High:11.00
52wk Low:5.60
Shares:30.26M
Float Shares:12.40M
Volume Ratio:1.30
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7983
EPS(LYR):-5.0200
ROE:-7029.26%
ROA:-17.43%
PB:-1.78
PE(LYR):-1.47

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Nuvalent, Sirius XM, J.M. Smucker

Reuters
·
Jun 09

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

TIPRANKS
·
Jun 09

BUZZ-Cartesian rises on China tie-up to develop new autoimmune cell therapy

Reuters
·
Jun 09

Cartesian Therapeutics - Westgene to Receive Upfront and Potential Milestone Payments Under Agreement

THOMSON REUTERS
·
Jun 09

Cartesian Therapeutics - Clinical Study to Initiate 2H 2026 With in-Human Data Expected 1H 2027

THOMSON REUTERS
·
Jun 09

Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma to Accelerate the Development of in Vivo CAR-T Platform in Autoimmune Diseases

THOMSON REUTERS
·
Jun 09

Cartesian Therapeutics - Clinical Trial With Descartes-8 Mrna and Westgene Lnp in Mg to Start 2H 2026

THOMSON REUTERS
·
Jun 09

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09

H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

TIPRANKS
·
May 27

Cartesian Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
May 27

Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures

TIPRANKS
·
May 26

Cartesian Therapeutics Inc - Phase 3 Aurora Topline Data In Myasthenia Gravis Expected In 1Q27 BLA Filing Planned Mid-2027

Reuters
·
May 26

Cartesian Therapeutics Inc - Enters Loan and Security Agreement on May 22 - SEC Filing

THOMSON REUTERS
·
May 26

Cartesian Therapeutics secures up to $150 million credit facility from K2 HealthVentures

Reuters
·
May 26

Cartesian Therapeutics Inc - Phase 3 Aurora Topline Data in Myasthenia Gravis Expected in 1Q27; Bla Filing Planned Mid-2027

THOMSON REUTERS
·
May 26

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing From K2 Healthventures and Expects Topline Data From the Phase 3 Aurora Trial in First Quarter 2027

THOMSON REUTERS
·
May 26

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 12

Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 12

Cartesian Therapeutics grants 317,200 inducement stock options at $6.22 exercise price

Reuters
·
May 04

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
May 04